NCT03147885 - Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Diffuse Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Extranodal Marginal Zone LymphomaRecurrent Follicular LymphomaRecurrent Indolent Adult Non-Hodgkin LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Waldenstrom MacroglobulinemiaRefractory B-Cell Non-Hodgkin LymphomaRefractory Extranodal Marginal Zone LymphomaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaStage III Non-Hodgkin LymphomaStage IV Non-Hodgkin LymphomaTransformed Recurrent Non-Hodgkin Lymphoma

Interventions

DRUG

Selinexor

Given PO

Trial Locations (1)

48201

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER